Table 2.
Trials investigating the duration of anti-HER2 therapy.
| Trial | Phase | Duration of trastuzumab | N | Efficacy versus 1-year trastuzumab | Cardiac events |
|---|---|---|---|---|---|
| HERA (48) | III | 2 years | 5099 | DFS (10y) 70% vs 72% | 7.3% vs 4.4% |
| PHARE (53) | III | 6 months | 3380 | DFS (3y) 87.7% vs 90.7% | 1.9% vs 5.7% |
| HORG (54) | III | 6 months | 481 | DFS (3y) 93.3% vs 95.7% | 0.8% vs 0% |
| PERSEPHONE (55) | III | 6 months | 4088 | DFS (4y) 89.4% vs 89.8% | 8% vs 11% |
| SOLD (56) | III | 9 weeks | 2174 | DFS (5y) 88% vs 90.5% | 2% vs 4% |
| ShortHER (58) | III | 9 weeks | 1253 | DFS (5y) 85% vs 88% | 4.3% vs 13.1% |